Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
VRTX 494.46 -11.32(-2.24%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
Other News for VRTX
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
3 Biotech Stocks That Could Have Investors Grinning Soon
Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight